[go: up one dir, main page]

US20060051375A1 - Rabbit skin comprising biological active substances and its use - Google Patents

Rabbit skin comprising biological active substances and its use Download PDF

Info

Publication number
US20060051375A1
US20060051375A1 US10/532,687 US53268705A US2006051375A1 US 20060051375 A1 US20060051375 A1 US 20060051375A1 US 53268705 A US53268705 A US 53268705A US 2006051375 A1 US2006051375 A1 US 2006051375A1
Authority
US
United States
Prior art keywords
rabbit
skin
vaccinia virus
skin according
rabbit skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/532,687
Other languages
English (en)
Inventor
Wing Cheung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanworld Pharmaceutical Rugao Co Ltd
Original Assignee
Vanworld Pharmaceutical Rugao Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32686811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20060051375(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vanworld Pharmaceutical Rugao Co Ltd filed Critical Vanworld Pharmaceutical Rugao Co Ltd
Assigned to VANWORLD PHARMACEUTICAL (RUGAO) COMPANY LIMITED reassignment VANWORLD PHARMACEUTICAL (RUGAO) COMPANY LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHEUNG, WING SUM
Publication of US20060051375A1 publication Critical patent/US20060051375A1/en
Priority to US12/880,856 priority Critical patent/US20110003009A1/en
Priority to US13/777,637 priority patent/US8900639B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/10—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from hair, feathers, horn, skins, leather, bones, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Definitions

  • the present invention relates to a rabbit skin containing biologically active substances and its use.
  • the objective of the present invention is to provide a rabbit skin which is rich in biologically highly active substances that can be used for preparing drugs and health foods.
  • the rabbit skin of the present invention is obtained by the process including vaccinating rabbit ( Oryctolagus cuniculus ) skin tissues with vaccinia virus, feeding rabbit vaccinated with vaccinia virus, killing the rabbit when its skin tissues is inflamed enough, and peeling the rabbit.
  • Vaccinia virus has been used widely since the 20th century. All kinds of vaccinia virus can be used to prepare the rabbit skin of the present invention, such as Lister strain, Ikeda strain, Dairen strain, EM-63 strain, Temple of Heaven strain, LMC strain, Tashkent strain, Williamsport strain, and New York City Board of Health strain.
  • the preferred strains are Lister strain, Ikeda strain, Dairen strain, EM-63 strain, the most preferred strain is Lister strain. All these vaccinia virus strains can be purchased from the market.
  • the vaccinia virus strains used in the present invention can be purchased strain or strain obtained from subculture with rabbit.
  • the preferred vaccination method is subcutaneous vaccination, the said vaccinating rabbit skin tissues with vaccinia virus is effected by injecting subcutaneously 0.1 ⁇ 0.4 ml solution containing 10 6 ⁇ 10 9 viruses/ml each site, 100 to 250 sites per rabbit weighing 1.5 ⁇ 3 Kg.
  • the rabbit used in preparing the rabbit skin of present invention can be all kinds of rabbits, such as Japanese white rabbit, New Zealand white rabbit, Chinese rabbit, Blue-violet rabbit, Silver Fox rabbit, Viennese rabbit, Long hair rabbit, Himalayan albio rabbit, Pex, Belgian Hare rabbit, Lop, California rabbit, Chekered Giant, Denmark white rabbit, West Germany long hair rabbit, the preferred rabbits are Japanese white rabbit, New Zealand white Rabbit, Chinese rabbit, Blue-violet rabbit, the most preferred rabbit is Japanese white rabbit.
  • rabbits such as Japanese white rabbit, New Zealand white rabbit, Chinese rabbit, Blue-violet rabbit, Silver Fox rabbit, Viennese rabbit, Long hair rabbit, Himalayan albio rabbit, Pex, Belgian Hare rabbit, Lop, California rabbit, Chekered Giant, Denmark white rabbit, West Germany long hair rabbit
  • the preferred rabbits are Japanese white rabbit, New Zealand white Rabbit, Chinese rabbit, Blue-violet rabbit, the most preferred rabbit is Japanese white rabbit.
  • the said killing the rabbit when its skin tissues is inflamed enough is effected when the rabbit skin inflammatory tissue shows visible blains accompanying with changing colour from redness to mauveness and becomes thick, and its subcuticle and hip become swollen.
  • the preferred method to kill rabbit is cervical vertebrae dislocation.
  • the rabbit skin of the present invention possesses 0.5 iu/g SART activity or more, and which also possesses the kallikrein-protease inhibition activity.
  • amino acids include glutamic acid, glycine, alanine, valine, isoleucine, leucine, tyrosine, phenylalanine, lysine, histidine, aspartic acid, threonine and serine.
  • nucleic acids include urocanic acid, uracil, hypoxanthine, xanthine and thymine.
  • Drug can be prepared by combining the biologically active preparations of the present invention with pharmaceutical acceptable adjuvants.
  • This drug can be various form of preparations used clinically, including injection and tablet, the preferred form is the injection.
  • the adjuvants can be for example injectable distilled water, normal saline, injectable vegetable oil, glucose injection, propylene glycol, polyethylene glycol, or it may be all kinds of stabilizers and emulsifiers.
  • the adjuvants can be excipients such as starch, lactose, mannitol; binders such as crystalline cellulose, arabic gum, corn starch, glutin, polyethylene, polyvinyl alcohol, polyvinyl-pyrrolidone; disintegrants such as carboxylmethyl cellulose, poly-ethylene glycol, potato starch; lubricants such as talcum powder, magnesium stearic acid; moistening agents such as glycerol.
  • the adjuvants can be fat oil, paraffin, wool fat, vaseline, glycol, glycerol.
  • the pharmacological and clinic experiments showed that the drugs prepared from the rabbit skin of the present invention have analgesic effect against all kinds of symptomatic neuralgia, lambago, cholecystagia, angina, arterial embolism pains, acute pains from wound, burn and scald, pains in surgery or post-surgery, peptic ulcer pain, dysmenorrhea, labor pains posterior to childbirth, headache, pains induced by various tumor and so on.
  • the drugs prepared from the rabbit skin of the present invention can effectively promote activation of macrophage, significantly inhibit 48-hour homologous PCA reaction induced by antibody of IgE in the model of type I allergic reaction in mice, inhibit the activity of anti-complement in type II allergic reaction.
  • the effects have linear correlation with the doses. So the drugs have effects on inhibiting inflammatory reaction correlated with immunity and improving immunity function.
  • the drugs prepared from the rabbit skin of the present invention have anti-allergic, anti-ulcer and sedative effects and so on.
  • the analgesic drugs of the present invention have little toxic effects.
  • Health food can be prepared by combining the biologically active preparations of the present invention with edible additives and nutritious substances, the said edible additives and nutritious substances include all kinds of vitamins and flavoring agents and so on. These kinds of health food have effects on improving immunity, alleviating pains, anti-allergy and anti-stress and so on.
  • the kallikrein-protease inhibition activity referred in this description is determined as follows:
  • the rabbit skin was cut in pieces of 1 cm 2 , 4 times (w/w) of 3% phenol aqueous solution was added, then placed the mixture at 4° C. for 72 h, centrifuged after liquid changed into emulsion. The supernatant was filtrated to collect brown solution A.
  • the brown solution A was boiled for 40 min in a water bath after pH was adjusted to 5.0 by 1M HCl, cooled to 28° C. promptly, centrifuged and filtrated to collect solution B.
  • the solution B was boiled for 40 min in a water bath after pH of filtrate was adjusted to 9.2 by 1M NaOH, cooled to 28° C. promptly, and filtrated to collect solution C.
  • test solution Effected reaction for 20 min at 30° C., and stopped the reaction by adding 0.8 ml of 1% citric acid.
  • the absorbance A of test solution was determined in 405 nm as the absorbance of control solution was initialized as 0.4. If A was less than 0.4, the rabbit skin from which the test solution was prepared was regarded as possessing the kallikrein-protease inhibition activity.
  • the dry variola vaccine of vaccinia virus Lister strain was dissolved by PBS( ⁇ ) (NaCl 80 g, KCl 2 g, NaH 2 PO 4 11.5 g, KH 2 PO 4 .2H 2 O 2 g, adding injectable H 2 O to 10 L) and well shaken. 0.4 ml of this solution was injected in central inner lamina of testicle of Japanese white rabbit. Dislocating its cervical vertebra on the fourth day. Cut the scrotum, removed connective tissue in the testicle. The testicle was placed in vessel full of ice, preserved at ⁇ 80° C. refrigerator.
  • the testicle was taken from refrigerator, softened for 1 h, grinded at 4° C., mixed in 1:1 with EAGLES' cultural medium (Eagle's powder 9.4 g, 10% NaHCO 3 12.5 ⁇ 22.0 ml, glutamine 10 ml, injectable H 2 O 1 L), packed, frozen at ⁇ 80° C. in refrigerator for 1 h, thawed at 37° C. in water bath, centrifuged with 3500 rpm at 4° C. for 20 min, packed by 10 ml.
  • the subculture antigen was preserved at ⁇ 80° C. in refrigerator.
  • the virus solution of subculture antigen was taken from the ⁇ 80° C. refrigerator, thawed at 30° C. in incubator.
  • the skin of rabbit was packed in plastic bag, preserved at ⁇ 18° C. in refrigerator prior to use.
  • the rabbit skin weighed 349 g, its SART activity was 0.85 iu/g, and its absorbance was 0.07. The results indicated that it possessed the kallikrein-protease inhibition activity.
  • the vaccinia virus Ikeda strain and New Zealand white rabbit were used to prepare the subculture antigen according to example 1.
  • the virus solution of subculture antigen was taken from the ⁇ 80° C. refrigerator, thawed at 30° C. in incubator. 5 ml of the virus solution was added into 500 ml of PBS( ⁇ ) by a 10-ml syringe, well shaken and diluted to injection of 10 9 virus/ml.
  • the vaccinia virus Dairen strain and Chinese rabbit were used to prepare the subculture antigen according to example 1.
  • the virus solution of subculture antigen was taken from the ⁇ 80° C. refrigerator, thawed at 30° C. in incubator. 5 ml of the virus solution was added into 500 ml of PBS( ⁇ ) by a 10-ml syringe, well shaken and diluted to injection of 10 6 virus/ml.
  • the vaccinia virus EM-63 strain and Blue-violet rabbit were used to prepare the subculture antigen according to example 1.
  • the virus solution of subculture antigen was taken from the ⁇ 80° C. refrigerator, thawed at 30° C. in incubator. 5 ml of the virus solution was added into 500 ml of PBS( ⁇ ) by a 10-ml syringe, well shaken and diluted to injection of 10 7 virus/ml.
  • the vaccinia virus Lister strain and New Zealand white rabbit were used to prepare the subculture antigen according to example 1.
  • the virus solution of subculture antigen was taken from the ⁇ 80° C. refrigerator, thawed at 30° C. in incubator. 5 ml of the virus solution was added into 500 ml of PBS( ⁇ ) by a 10-ml syringe, well shaken and diluted to injection of 10 9 virus/ml.
  • the rabbit When inflammatory tissue showed that skin surface had visible blains accompanying with changing colour from redness to mauveness and skin became thick, and subcuticle and hip became swollen, the rabbit was killed by cervical vertebra dislocation and peeled in 15 min. The skin of rabbit was packed in plastic bag, preserved at ⁇ 18° C. in refrigerator prior to use. The skin of rabbit weighed 310 g, its SART activity was 0.79 iu/g, and its absorbance was 0.09. The results indicated that it possessed the kallikrein-protease inhibition activity.
  • the vaccinia virus Lister strain and Chinese rabbit were used to prepare the subculture antigen according to example 1.
  • the virus solution of subculture antigen was taken from the ⁇ 80° C. refrigerator, thawed at 30° C. in incubator. 5 ml of the virus solution was added into 500 ml of PBS( ⁇ ) by a 10-ml syringe, well shaken and diluted to injection of 10 6 virus/ml.
  • the vaccinia virus Lister strain and Blue-violet rabbit were used to prepare the subculture antigen according to example 1.
  • the virus solution of subculture antigen was taken from the ⁇ 80° C. refrigerator, thawed at 30° C. in incubator. 5 ml of the virus solution was added into 500 ml of PBS( ⁇ ) by a 10-ml syringe, well shaken and diluted to injection of 107 virus/ml.
  • the vaccinia virus Ikeda strain and Japanese white rabbit were used to prepare the subculture antigen according to example 1.
  • the virus solution of subculture antigen was taken from the ⁇ 80° C. refrigerator, thawed at 30° C. in incubator. 5 ml virus solution was added into 500 ml PBS ( ⁇ ) by a 10-ml syringe, well shaken and diluted to injection of 10 9 virus/ml.
  • the rabbit When inflammatory tissue showed that skin surface had visible blains accompanying with changing colour from redness to mauveness and skin became thick, and subcuticle and hip became swollen, the rabbit was killed by cervical vertebra dislocation and peeled in 15 min. The skin of rabbit was packed in plastic bag, preserved at ⁇ 18° C. in refrigerator prior to use. The skin of rabbit weighed 335 g, its SART activity was 0.70 iu/g, and its absorbance was 0.12. The results indicated that it possessed the kallikrein-protease inhibition activity.
  • the vaccinia virus Dairen strain and Japanese white rabbit were used to prepare for the subculture antigen according to example 1.
  • the virus solution of subculture antigen was taken from the ⁇ 80° C. refrigerator, thawed at 30° C. in incubator. 5 ml of the virus solution was added into 500 ml of PBS ( ⁇ ) by a 10-ml syringe, well shaken and diluted to injection of 106 virus/ml.
  • the vaccinia virus EM-63 strain and Japanese white rabbit were used to prepare the subculture antigen according to example 1.
  • the virus solution of subculture antigen was taken from the ⁇ 80° C. refrigerator, thawed at 30° C. in incubator. 5 ml of the virus solution was added into 500 ml of PBS( ⁇ ) by a 10-ml syringe, well shaken and diluted to injection of 10 7 virus/ml.
  • the analgesic injection was prepared by formula below using regular method. Preparation from rabbit skin according to example 2 5 ml NaCl 2.6 g Injectable distilled water 300 ml
  • the analgesic tablet was prepared by formula below using regular method. Preparation from rabbit skin according to example 1 50 ml Lactose 125 mg Crystalline cellulose 20 g Magnesium stearic acid 5 mg
  • the health food was prepared by formula below using regular method. Preparation from rabbit skin according to example 1 50 ml Sucrose 125 mg Citric acid 20 mg Vitamin C 5 mg Water 1000 ml

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
US10/532,687 2002-10-31 2003-10-30 Rabbit skin comprising biological active substances and its use Abandoned US20060051375A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/880,856 US20110003009A1 (en) 2002-10-31 2010-09-13 Process for obtaining a rabbit skin comprising biological active substances
US13/777,637 US8900639B2 (en) 2002-10-31 2013-02-26 Process for obtaining a rabbit skin comprising biological active substances

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNB021459754A CN1207005C (zh) 2002-10-31 2002-10-31 含生物活性物质的兔皮和其用途
CN02145975.4 2002-10-31
PCT/CN2003/000923 WO2004060381A1 (fr) 2002-10-31 2003-10-30 Peau de lapin comprenant une substance bioactive et son utilisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/880,856 Continuation US20110003009A1 (en) 2002-10-31 2010-09-13 Process for obtaining a rabbit skin comprising biological active substances

Publications (1)

Publication Number Publication Date
US20060051375A1 true US20060051375A1 (en) 2006-03-09

Family

ID=32686811

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/532,687 Abandoned US20060051375A1 (en) 2002-10-31 2003-10-30 Rabbit skin comprising biological active substances and its use
US12/880,856 Abandoned US20110003009A1 (en) 2002-10-31 2010-09-13 Process for obtaining a rabbit skin comprising biological active substances
US13/777,637 Expired - Lifetime US8900639B2 (en) 2002-10-31 2013-02-26 Process for obtaining a rabbit skin comprising biological active substances

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/880,856 Abandoned US20110003009A1 (en) 2002-10-31 2010-09-13 Process for obtaining a rabbit skin comprising biological active substances
US13/777,637 Expired - Lifetime US8900639B2 (en) 2002-10-31 2013-02-26 Process for obtaining a rabbit skin comprising biological active substances

Country Status (7)

Country Link
US (3) US20060051375A1 (fr)
EP (1) EP1557171A4 (fr)
KR (2) KR20050072768A (fr)
CN (1) CN1207005C (fr)
AU (1) AU2003280918A1 (fr)
NZ (1) NZ540428A (fr)
WO (1) WO2004060381A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060134139A1 (en) * 2004-12-01 2006-06-22 Masaharu Kurohashi Dried product and a process for manufacturing the product
EP2364711A4 (fr) * 2008-11-11 2012-12-12 Vanworld Pharmaceutical Rugao Co Ltd Utilisation d'extraits provenant de peau de lapin enflammée par le virus de la vaccine pour la fabrication d'un médicament destinée au traitement d'une maladie cérébro-vasculaire aiguë
US9884077B2 (en) 2013-04-30 2018-02-06 Nippon Zoki Pharmaceutical Co., Ltd. Extract and preparation containing said extract
EP3421989A4 (fr) * 2016-02-24 2019-08-14 Osaka University Procédé de test
CN111904981A (zh) * 2020-09-07 2020-11-10 威世药业（如皋）有限公司 一种痘苗病毒致炎兔皮生产方法
CN115212235A (zh) * 2022-07-25 2022-10-21 威世药业（如皋）有限公司 一种稀释后痘苗病毒致炎兔皮生产方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1207005C (zh) 2002-10-31 2005-06-22 威世药业（如皋）有限公司 含生物活性物质的兔皮和其用途
AU2003280684B2 (en) * 2002-10-31 2009-06-25 Nippon Zoki Pharmaceutical Co., Ltd. Remedy for fibromyalgia
CN1613305B (zh) * 2004-12-06 2011-01-12 威世药业（如皋）有限公司 一种从含新型活性物质的兔皮中提取的活性制剂
KR101853254B1 (ko) 2012-05-25 2018-05-02 웰 리소시스 리미티드 펩타이드 및 그의 용도
CN103357006B (zh) 2012-10-10 2014-10-15 日本脏器制药株式会社 含有提取物的制剂的检查方法
JP5490939B2 (ja) * 2013-04-19 2014-05-14 日本臓器製薬株式会社 抽出物及び製剤
EP3305307A4 (fr) * 2015-05-29 2019-02-20 Nippon Zoki Pharmaceutical Co., Ltd. Promoteur de migration de cellules souches pluripotentes
CN105663166B (zh) * 2016-03-02 2020-04-17 中国人民解放军疾病预防控制所 特异性抗天花病毒感染模型毒株的生物活性制剂及应用
CN109512838B (zh) * 2017-09-15 2022-05-10 天津小西生物医药科技有限公司 一种兔皮提取物及其制备方法和用途
EP3957314A4 (fr) 2019-04-17 2022-12-07 Nexus Bio-Drug Development Limited Utilisation d'extrait de peau de lapin enflammée par le virus de la vaccine dans le traitement d'une lésion du système hématopoïétique
JP7488588B2 (ja) 2019-06-14 2024-05-22 俊熙有限公司 ワクシニアウイルスによって炎症を起こしたウサギ皮膚由来の抽出物のがん治療における使用
RU2707948C1 (ru) * 2019-09-02 2019-12-02 Виктор Александрович Сисев Фармацевтическая композиция для парентерального капельного введения (варианты)
CN111944042A (zh) * 2020-09-07 2020-11-17 威世药业（如皋）有限公司 一种蛋白-a抗原的制备工艺
CN111956669A (zh) * 2020-09-07 2020-11-20 威世药业（如皋）有限公司 一种牛痘疫苗致炎兔皮提取物注射液制造工艺

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057324A (en) * 1987-07-23 1991-10-15 Nippon Zoki Pharmaceutical Co., Ltd. Kallikrein inhibitor substance, a process for preparation and pharmaceutical compositions thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3455784A (en) * 1966-03-11 1969-07-15 American Home Prod Control of enzyme activity in frozen systems
US3949073A (en) * 1974-11-18 1976-04-06 The Board Of Trustees Of Leland Stanford Junior University Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution
JPS53101515A (en) 1977-02-17 1978-09-05 Nippon Zoki Pharmaceutical Co Medicine having anodyne * sedative and antiallergic activity and production thereof
JPS578741A (en) * 1980-06-17 1982-01-18 Eisai Co Ltd Quality improvement of animal fur
FR2564320B1 (fr) 1984-05-18 1986-10-17 Pasteur Institut Procede de production de vaccin antirabique sur des cultures de lignees de cellules non tumorigenes de lapin, vaccin antirabique obtenu par ce procede et nouvelles lignees cellulaires utilisables pour la production dudit vaccin
JPS6339572A (ja) * 1986-08-05 1988-02-20 株式会社チノー 葉たばこ乾燥装置
US4798171A (en) * 1987-07-09 1989-01-17 Nu Aire, Inc. Animal isolator
US4985254A (en) * 1987-11-06 1991-01-15 Nippon Zoki Pharmaceutical Co., Ltd. Method of treating ischemic diseases
ES2059816T3 (es) * 1988-04-30 1994-11-16 Nippon Zoki Pharmaceutical Co Sustancias activas fisiologicamente, un procedimiento para la preparacion y composiciones farmaceuticas de las mismas.
JP2539665B2 (ja) * 1988-06-20 1996-10-02 日本臓器製薬株式会社 神経疾患治療剤
US5225331A (en) * 1991-04-25 1993-07-06 National Research Council Of Canada Immunoassay for detecting group b streptococcus
JP2594222B2 (ja) 1993-09-28 1997-03-26 日本臓器製薬株式会社 新規生理活性物質−ｋｆ
US6019988A (en) * 1996-11-18 2000-02-01 Bristol-Myers Squibb Company Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage
JP4033936B2 (ja) * 1997-01-08 2008-01-16 日本臓器製薬株式会社 一酸化窒素産生抑制剤
JPH1180005A (ja) * 1997-09-12 1999-03-23 Nippon Zoki Pharmaceut Co Ltd 骨粗鬆症治療剤
JPH11139977A (ja) * 1997-11-07 1999-05-25 Nippon Zoki Pharmaceut Co Ltd Ｎｅｆ作用抑制剤
US5960635A (en) * 1998-03-03 1999-10-05 Dakhil; Farouk Air conditioning apparatus using liquid nitrogen
CA2270050A1 (fr) * 1998-04-27 1999-10-27 Jin-Emon Konishi Agent therapeutique pour maladies ischemiques
CN100425692C (zh) 1998-06-02 2008-10-15 株式会社富吉摩托普拉泽兹 含有高质量生理活性的家兔发痘组织的制造方法
CN1055249C (zh) * 1998-07-15 2000-08-09 沈继平 一种镇痛药和其制造方法
KR20000076874A (ko) * 1999-03-19 2000-12-26 고니시 진우에몬 케모카인 생산 촉진제
JP2001058949A (ja) * 1999-08-20 2001-03-06 Fujimoto Brothers:Kk 抗ショック剤
JP4612924B2 (ja) * 1999-08-20 2011-01-12 藤本製薬株式会社 サイトカイン調節剤
MXPA04005577A (es) * 2001-12-10 2005-04-19 Bavarian Nordic As Formulaciones que contienen poxvirus y proceso para la preparacion de composiciones estables que contienen poxvirus.
CN1207005C (zh) 2002-10-31 2005-06-22 威世药业（如皋）有限公司 含生物活性物质的兔皮和其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057324A (en) * 1987-07-23 1991-10-15 Nippon Zoki Pharmaceutical Co., Ltd. Kallikrein inhibitor substance, a process for preparation and pharmaceutical compositions thereof

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060134139A1 (en) * 2004-12-01 2006-06-22 Masaharu Kurohashi Dried product and a process for manufacturing the product
US8568789B2 (en) 2004-12-01 2013-10-29 Nippon Zoki Pharmaceutical Co., Ltd. Dried product and a process for manufacturing the product
EP2364711A4 (fr) * 2008-11-11 2012-12-12 Vanworld Pharmaceutical Rugao Co Ltd Utilisation d'extraits provenant de peau de lapin enflammée par le virus de la vaccine pour la fabrication d'un médicament destinée au traitement d'une maladie cérébro-vasculaire aiguë
US10265345B2 (en) 2008-11-11 2019-04-23 Vanworld Pharmaceutical (Rugao) Co., Ltd. Use of extracts from rabbit skin inflamed by vaccinia virus for the manufacture of a medicament for the treatment of acute cerebrovascular disease
US9884077B2 (en) 2013-04-30 2018-02-06 Nippon Zoki Pharmaceutical Co., Ltd. Extract and preparation containing said extract
EP3421989A4 (fr) * 2016-02-24 2019-08-14 Osaka University Procédé de test
US11129976B2 (en) 2016-02-24 2021-09-28 Osaka University Test method
CN111904981A (zh) * 2020-09-07 2020-11-10 威世药业（如皋）有限公司 一种痘苗病毒致炎兔皮生产方法
CN115212235A (zh) * 2022-07-25 2022-10-21 威世药业（如皋）有限公司 一种稀释后痘苗病毒致炎兔皮生产方法

Also Published As

Publication number Publication date
AU2003280918A1 (en) 2004-07-29
CN1493302A (zh) 2004-05-05
AU2003280918A8 (en) 2004-07-29
CN1207005C (zh) 2005-06-22
EP1557171A1 (fr) 2005-07-27
KR20080048536A (ko) 2008-06-02
US20130183386A1 (en) 2013-07-18
WO2004060381A8 (fr) 2006-08-10
KR20050072768A (ko) 2005-07-12
NZ540428A (en) 2007-11-30
US20110003009A1 (en) 2011-01-06
EP1557171A4 (fr) 2006-08-09
US8900639B2 (en) 2014-12-02
WO2004060381A1 (fr) 2004-07-22

Similar Documents

Publication Publication Date Title
US8900639B2 (en) Process for obtaining a rabbit skin comprising biological active substances
JP2002526452A (ja) キョウチクトウ抽出物、その医薬組成物及びその調整方法
WO2015176558A1 (fr) Composition de vitamine c naturelle et de peptide de collagène d'écailles de poisson et leurs procédés de préparation
CN104161180A (zh) 一种抗猪病毒性疾病的饲料添加剂、制备方法及应用
CN115120604A (zh) 芹菜素7-o-葡萄糖苷作为降尿酸和痛风性关节炎制剂的应用
JPH09507237A (ja) スッポンとカメの組成物
CN103520360A (zh) 一种中药复方制剂、其制备方法及其应用
CN104161179B (zh) 一种抗犬病毒性疾病的饲料添加剂、制备方法及应用
CN101647813A (zh) 一种动物药的仿生酶解产物及其用途
KR102234860B1 (ko) 싸리 추출물을 포함하는 근위축 예방 및 치료용 조성물
JPH0643330B2 (ja) 麦類青汁系血糖降下剤
CN104161178B (zh) 一种抗鸭病毒性疾病的饲料添加剂、制备方法及应用
CN104208683B (zh) 一种抗鸭病毒性疾病的药物组合物、冻干粉、制备方法及应用
CN104161183B (zh) 一种抗鸡病毒性疾病的饲料添加剂、制备方法及应用
CN109045295A (zh) 一种疫苗佐剂的应用及其制备方法
CN108187032A (zh) 虫草胶原蛋白肽片
CN102212109B (zh) 从骨肽注射剂中分离的骨多肽化合物及其应用
CN120682308B (zh) 牛骨髓肽及其在提高免疫力中的应用
CN101686992B (zh) 卡介菌多糖核酸提取物在制备治疗变态反应性皮肤病的药物中的应用及其注射剂和制备方法
CN104161182B (zh) 一种抗鹅病毒性疾病的饲料添加剂、制备方法及应用
CN115005449B (zh) 一种肿瘤术后复合天然植物蛋白营养餐食及其制作方法
JPS63112522A (ja) トナカイの角からなる滋養強壮薬品
CN120682308A (zh) 牛骨髓肽及其在提高免疫力中的应用
KR101847479B1 (ko) 강진향 추출물을 포함하는 백선의 예방 또는 치료용 조성물
KR20150078924A (ko) 작약 추출물을 유효 성분으로 포함하는 인플라마좀 매개 염증성 질환 예방, 개선용 조성물

Legal Events

Date Code Title Description
AS Assignment

Owner name: VANWORLD PHARMACEUTICAL (RUGAO) COMPANY LIMITED, C

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHEUNG, WING SUM;REEL/FRAME:017259/0440

Effective date: 20050322

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION